The Exchange has sought clarification from Granules India Limited with respect to recent news item captioned Pharma stocks slump as Trump shoots letters to 17 global drug majors seeking lower prices. The response from the Company is attached.
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts less than Nifty Smallcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
NSE sought clarification from Granules India after its share price dropped following a Moneycontrol news item about Trump sending letters to 17 global pharma majors seeking lower drug prices. The company clarified that it has NOT received any communication from the US government or any related authority. Granules India is not among the 17 companies listed (which include AbbVie, Pfizer, Merck, Novartis, etc.). There are no ongoing negotiations, regulatory proceedings, or undisclosed price-sensitive information related to this matter. The company confirmed full compliance with SEBI disclosure regulations and stated the news item does not factually apply to it.
This clarification should reassure investors that the stock movement was due to broad sector-wide sentiment rather than any company-specific action against Granules India. Short-term sentiment may recover as the company's non-involvement is confirmed, though the pharma sector may remain under pressure from US drug pricing concerns.